159 related articles for article (PubMed ID: 21530512)
1. microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma.
Zhou C; Liu J; Li Y; Liu L; Zhang X; Ma CY; Hua SC; Yang M; Yuan Q
FEBS Lett; 2011 Jun; 585(12):1828-34. PubMed ID: 21530512
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9.
Kohga K; Takehara T; Tatsumi T; Ishida H; Miyagi T; Hosui A; Hayashi N
Hepatology; 2010 Apr; 51(4):1264-73. PubMed ID: 20099300
[TBL] [Abstract][Full Text] [Related]
3. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.
Shimizu S; Takehara T; Hikita H; Kodama T; Miyagi T; Hosui A; Tatsumi T; Ishida H; Noda T; Nagano H; Doki Y; Mori M; Hayashi N
J Hepatol; 2010 May; 52(5):698-704. PubMed ID: 20347499
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
5. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.
Chen KF; Chen HL; Tai WT; Feng WC; Hsu CH; Chen PJ; Cheng AL
J Pharmacol Exp Ther; 2011 Apr; 337(1):155-61. PubMed ID: 21205925
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
7. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
8. MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
Chen Y; Feng F; Gao X; Wang C; Sun H; Zhang C; Zeng Z; Lu Y; An L; Qu J; Wang F; Yang Y
Curr Cancer Drug Targets; 2015; 15(3):176-87. PubMed ID: 25714700
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest.
Xu Y; Xia F; Ma L; Shan J; Shen J; Yang Z; Liu J; Cui Y; Bian X; Bie P; Qian C
Cancer Lett; 2011 Nov; 310(2):160-9. PubMed ID: 21802841
[TBL] [Abstract][Full Text] [Related]
10. Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma.
Chiou JF; Tai CJ; Huang MT; Wei PL; Wang YH; An J; Wu CH; Liu TZ; Chang YJ
Ann Surg Oncol; 2010 Feb; 17(2):603-12. PubMed ID: 19830497
[TBL] [Abstract][Full Text] [Related]
11. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.
Shi YH; Ding ZB; Zhou J; Hui B; Shi GM; Ke AW; Wang XY; Dai Z; Peng YF; Gu CY; Qiu SJ; Fan J
Autophagy; 2011 Oct; 7(10):1159-72. PubMed ID: 21691147
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.
Sass G; Klinger N; Sirma H; Hashemolhosseini S; Hellerbrand C; Neureiter D; Wege H; Ocker M; Tiegs G
Int J Oncol; 2011 Aug; 39(2):433-42. PubMed ID: 21567083
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosis.
Li XF; Gong RY; Wang M; Yan ZL; Yuan B; Wang K; Shi LH
Biochem Biophys Res Commun; 2012 Feb; 418(3):531-6. PubMed ID: 22285185
[TBL] [Abstract][Full Text] [Related]
14. [The relationship between microRNA-18 and BTG2 in the carcinogenesis of hepatocellular carcinoma].
Li Q; Wang G; Zhang ZM
Zhonghua Gan Zang Bing Za Zhi; 2009 Jan; 17(1):42-5. PubMed ID: 19203451
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells.
Liu WH; Yeh SH; Lu CC; Yu SL; Chen HY; Lin CY; Chen DS; Chen PJ
Gastroenterology; 2009 Feb; 136(2):683-93. PubMed ID: 19027010
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.
Bai S; Nasser MW; Wang B; Hsu SH; Datta J; Kutay H; Yadav A; Nuovo G; Kumar P; Ghoshal K
J Biol Chem; 2009 Nov; 284(46):32015-27. PubMed ID: 19726678
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
Sieghart W; Pinter M; Dauser B; Rohr-Udilova N; Piguet AC; Prager G; Hayden H; Dienes HP; Dufour JF; Peck-Radosavljevic M
J Hepatol; 2012 Sep; 57(3):592-9. PubMed ID: 22634341
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1.
Wong QW; Lung RW; Law PT; Lai PB; Chan KY; To KF; Wong N
Gastroenterology; 2008 Jul; 135(1):257-69. PubMed ID: 18555017
[TBL] [Abstract][Full Text] [Related]
20. Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells.
Ou DL; Shen YC; Yu SL; Chen KF; Yeh PY; Fan HH; Feng WC; Wang CT; Lin LI; Hsu C; Cheng AL
Cancer Res; 2010 Nov; 70(22):9309-18. PubMed ID: 21062976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]